[
  {
    "ts": null,
    "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
    "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
    "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770453000,
      "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
      "id": 138384854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154390775/image_2154390775.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
      "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d"
    }
  },
  {
    "ts": null,
    "headline": "BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=c7e792ff23371049a31794ebd51b7385b62a3973c2f396637236f211cd0c91c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770442309,
      "headline": "BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds",
      "id": 138393001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=c7e792ff23371049a31794ebd51b7385b62a3973c2f396637236f211cd0c91c4"
    }
  },
  {
    "ts": null,
    "headline": "Why Biogen Stock Surged Almost 9% Higher on Friday",
    "summary": "It's obvious that the company has a good shot at returning to growth.",
    "url": "https://finnhub.io/api/news?id=0852201a7b339b5eb07c3ca51c2e7fb985151540cb6fab61869c3c79b54c2ad4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770426421,
      "headline": "Why Biogen Stock Surged Almost 9% Higher on Friday",
      "id": 138381722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "It's obvious that the company has a good shot at returning to growth.",
      "url": "https://finnhub.io/api/news?id=0852201a7b339b5eb07c3ca51c2e7fb985151540cb6fab61869c3c79b54c2ad4"
    }
  }
]